Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for a new cardiovascular risk reduction claim, as it faces increased competition from Novo Nordisk. The US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results